Search Results

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (Protocol v.00) MOA: Dabrafenib is a RAF kinase inhibitor. Trametinib is an allosteric inhibitor of MEK1/2 and kinase activity. Key Eligibility: Documented BRAF V600E mutation-positive solid tumor Study participants previously not treated…

A Global, Phase 3, Randomized, Multicenter, Open-label Study ToEvaluate The Efficacy And Safety Of Firmonertinib Compared WithInvestigator’s Choice Of Osimertinib Or Afatinib As First-line Treatment InParticipants Who Have Locally Advanced Or Metastatic Non-small-cellLung Cancer With Epidermal Growth Factor Receptor P-loop And AlphaC-helix Compressing (PACC) Uncommon Mutations (ALPACCA) MOA: Firmonertinib is an oral EGFR inhibitor with…

A Phase 3 Multicenter Double-blind Randomized Study Of Taletrectinib Versus Placebo In Patients With ROS1-fusion Positive Stage IB-IIIA Non-small Cell Lung Cancer Who Have Undergone Complete Tumor Resection (TRUST-IV) MOA: Taletrectinib (AB-106 or DS-6051b) is a ROS1 tyrosine kinase inhibitor (TKI) effective against ROS1 and acquired resistance mutations. Key Eligibility: Histologically confirmed stage IB, II,…

A Prospective Low-interventional Phase 4 Single Arm Study Of Ocular Assessments In Patients Treated With Tivdak® In Recurrent Or Metastatic Cervical Cancer MOA: Tisotumab vedotin-tftv (Tivdak®) is a tissue factor (TF)-directed ADC with an MMAE payload. Key Eligibility: Recurrent/metastatic cervical cancer with PD on/afterchemotherapy Tivdak recommended by physician according to US prescribinginformation Must be willing…

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation MOA: Rezatapopt (PC14586) is a p53 reactivator that selectively binds to the mutated p53 Y220C protein and restores p53 WT activity. Key Eligibility Histologically…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER 050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) MOA: Elritercept is a recombinant fusion protein designed to inhibit signaling by select TGF-β superfamily ligands, including activin A,…